Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Influence of Apolipoprotein A-I and B Genetic Variations on Insulin Resistance and Metabolic Syndrome in Obstructive Sleep Apnea
37 Pages Posted: 4 Feb 2019
More...Abstract
Background: Both apolipoprotein A-I (APOA-I) and apolipoprotein B (APOB) are associated with insulin resistance, metabolic syndrome (MetS), and obstructive sleep apnea (OSA). However, whether multiple single nucleotide polymorphism (SNP) variants of APOA-I and APOB exert a collaborative effect on insulin resistance and MetS in OSA remains uncertain.
Methods: Initially, 12 APOA-I SNPs and 30 APOB SNPs in 5,259 subjects were examined. After strict screening, four APOA-I SNPs and five APOB SNPs in 4,007 participants were included in this study. For each participant, the genetic risk score (GRS) was calculated based on the cumulative effect of multiple genetic variants of APOA-I and APOB. Logistic regression analyses were used to evaluate the relationships between APOA-I/APOB genetic polymorphisms, insulin resistance, and MetS.
Results: Patients with insulin resistance had a lower APOA-I GRS and higher APOB/APOA-I and APOB levels after adjustments [odds ratio (OR) = 0.917, P = 0.001; OR = 2.285, P < 0.001; OR = 3.168, P < 0.001, respectively]. Individuals with MetS had a lower APOA-I GRS and APOA-I level and higher APOB/APOA-I and APOB levels after adjustments (OR = 0.870, 0.09, 14.488, 6.098, respectively, all P < 0.001). In addition, individuals in the top quintile of the APOA-I genetic score distribution had a lower risk of insulin resistance and MetS after adjustments (OR = 0.761, P = 0.007; OR = 0.637, P < 0.001, respectively).
Conclusion: In patients with OSA, APOA-I genetic variation contributes to insulin resistance and MetS, whereas APOB genetic variation contributes to MetS only.
Funding Statement: National Key R&D Program of China (2017YFC0112500); National Natural Science Foundation of China (81770987, 81700896, 81701306, 81770988); Innovation Program of Shanghai Municipal Education Commission (2017-01-07-00-02-E00047); multi-center clinical research project from school of medicine, Shanghai Jiao Tong University (DLY201502) and Shanghai Shen-Kang Hospital Management Center Project (SHDC12015101).
Declaration of Interests: The authors declare that they have no competing interests.
Ethics Statement Approval: The ethics committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital approved this study according to Helsinki Declaration II. All the participants have given the informed consent before taking part in the study.
Keywords: apolipoprotein A-I; apolipoprotein B; genetic risk score; insulin resistance; metabolic syndrome; obstructive sleep apnea
Suggested Citation: Suggested Citation